Bristol Myers Squibb (NYSE:BMY) Price Target Raised to $73.00 at JPMorgan Chase & Co.

Bristol Myers Squibb (NYSE:BMY) had its price objective upped by JPMorgan Chase & Co. from $67.00 to $73.00 in a research report released on Friday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biopharmaceutical company’s stock.

Other analysts have also recently issued reports about the company. Raymond James Financial reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday. UBS Group reissued a “buy” rating on shares of Bristol Myers Squibb in a research note on Thursday, May 28th. Bank of America cut their price target on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating on the stock in a report on Friday, July 10th. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Finally, Truist Financial reiterated a “buy” rating and issued a $70.00 price objective (up from $65.00) on shares of Bristol Myers Squibb in a research note on Friday. Nine research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $63.24.

Bristol Myers Squibb Trading Up 0.9%

Shares of BMY stock opened at $65.44 on Friday. Bristol Myers Squibb has a fifty-two week low of $42.52 and a fifty-two week high of $65.66. The company has a 50 day moving average price of $58.02 and a 200 day moving average price of $58.34. The stock has a market capitalization of $133.62 billion, a P/E ratio of 14.41, a price-to-earnings-growth ratio of 0.18 and a beta of 0.23. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 69.75%. The company had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. During the same period in the prior year, the business earned $1.46 EPS. The firm’s quarterly revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities research analysts predict that Bristol Myers Squibb will post 6.34 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 2nd will be paid a dividend of $0.63 per share. The ex-dividend date is Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.9%. Bristol Myers Squibb’s payout ratio is presently 55.51%.

Institutional Trading of Bristol Myers Squibb

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bank & Trust Co boosted its position in shares of Bristol Myers Squibb by 1.0% during the 2nd quarter. Bank & Trust Co now owns 20,387 shares of the biopharmaceutical company’s stock worth $1,175,000 after acquiring an additional 207 shares in the last quarter. Wedge Capital Management L L P NC raised its position in shares of Bristol Myers Squibb by 7.1% during the 2nd quarter. Wedge Capital Management L L P NC now owns 528,057 shares of the biopharmaceutical company’s stock worth $30,427,000 after acquiring an additional 35,072 shares in the last quarter. Annex Advisory Services LLC raised its position in shares of Bristol Myers Squibb by 7.7% during the 2nd quarter. Annex Advisory Services LLC now owns 5,373 shares of the biopharmaceutical company’s stock worth $310,000 after acquiring an additional 384 shares in the last quarter. Tema ETFs LLC lifted its stake in Bristol Myers Squibb by 6.4% during the second quarter. Tema ETFs LLC now owns 164,530 shares of the biopharmaceutical company’s stock worth $9,480,000 after purchasing an additional 9,933 shares during the last quarter. Finally, Canvas Wealth Advisors LLC boosted its holdings in Bristol Myers Squibb by 18.9% in the second quarter. Canvas Wealth Advisors LLC now owns 4,554 shares of the biopharmaceutical company’s stock valued at $262,000 after purchasing an additional 724 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Strong Q2 results and raised guidance: Bristol Myers reported adjusted EPS of $2.04 versus the $1.60 consensus and revenue of $12.97 billion versus expectations of $11.74 billion. Revenue rose 5.7% year over year. Management raised 2026 EPS guidance to $6.75-$7.00 and revenue guidance to $49-$50 billion, both above Wall Street estimates. Bristol Myers raises 2026 forecast as Eliquis, newer medicines power results
• Positive Sentiment: Growth products are gaining momentum: Eliquis sales, along with newer medicines including Camzyos, Reblozyl, Opdivo Qvantig and Breyanzi, drove results. The growth portfolio now contributes roughly 60% of revenue, helping offset pressure from older products. Bristol-Myers Squibb Q2 2026 earnings call transcript
• Positive Sentiment: Several analysts raised targets: JPMorgan lifted its target from $67 to $73 and maintained an “overweight” rating, while Truist raised its target from $65 to $70 and reaffirmed “buy.” These revisions suggest analysts see additional upside following the earnings beat.
• Neutral Sentiment: Valuation is back in focus: Analysts note that BMY’s strong performance and recent rally have reduced the margin of safety, despite relatively attractive valuation and dividend support. RBC raised its target to $64 but retained a “sector perform” rating, implying the shares may remain range-bound. Bristol-Myers Squibb’s Catalyst Delays May Keep Stock Range-Bound, RBC Says
• Negative Sentiment: Pipeline timing and legacy declines remain risks: Delayed readouts or launches for Milvexian and Cobenfy, along with declines in older medicines such as Opdivo, could temper the growth outlook and postpone upcoming catalysts.
• Negative Sentiment: Bearish options activity: Traders purchased 44,620 put options, about 77% above typical daily volume, signaling increased hedging or speculation on downside risk.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.